Technical
Channels

Drug Discovery

Drug Development

Drug Manufacturing

Drug Delivery

Clinical Trials

Regulatory and Legal

Alliances and Mergers

QA/QC and Compliance

Pharmaceutical Processing and Packaging

Change text size [+] [-]

Pall Corp's Q4 sales up 11.9%

Friday, October 10, 2008
 Email This |  Printer Friendly

Pall Corporation's fourth quarter sales grew to $723.2 million, an 11.9% increase over the fourth quarter of fiscal 2007.

Diluted earnings per share (EPS) were $0.57, up from $0.13 a year earlier.

Net earnings were $69.9 million, compared to $16.8 million.

Pro forma EPS, excluding restructuring and other charges, were $0.61 versus last year's $0.46, an increase of 32.6%.

Within life sciences, biopharmaceuticals sales increased 4.6% in the quarter, and 10.8% for the full year.

The company says it will continue to win business for new drugs and factories as evidenced by the 41.1% increase in systems sales in the year.

It is also benefitting from increased production of biotechnology drugs and vaccines.

The recent acquisition of GeneSystems further expands Pall's capabilities in the biopharmaceuticals, medical, food and water safety markets.


Share this:   Del.icio.us | 
Ask the Expert

What technologies and/or practices can Asian pharma manufacturers adopt today, to ensure quality in their products?

Digital Edition



Singapore's Preclinical R&D industry should differentiate itself in Asia by competing on quality rather than on price.
Yes
No
View results


ABOUT PHARMA ASIA | FREE SUBSCRIPTION | CONTACT US

© 2010 Ten Alps Communications Asia. All rights reserved.
Use of this Web site is subjected to its Terms and Conditions of Use. View our Privacy Policy